- |||||||||| Retrospective data, Journal: Paratesticular rhabdomyosarcoma: Importance of initial therapy. (Pubmed Central) - Feb 3, 2017
Scrotal violation remains a problem in paratesticular rhabdomyosarcoma and is a predictor of disease progression unless adequately treated. The risk of progression could be reduced with appropriate initial resection.
- |||||||||| Journal: Perioperative evaluation of medical comorbidities at a comprehensive cancer center. (Pubmed Central) - Feb 3, 2017
The identification and optimization of comorbid medical conditions such as diabetes and cardiovascular disease are important because they are known to predict clinical outcomes. Future work should focus on optimal perioperative management strategies to reduce risk of complications in patient with cancer and comorbidities.
- |||||||||| Trial primary completion date: The Oncopanel Pilot (TOP) Study (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=432, Active, not recruiting, [Table: see text]. Trial primary completion date: Nov 2016 --> Mar 2017
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Feb 3, 2017 P1/2, N=40, Active, not recruiting, Trial primary completion date: Nov 2016 --> Mar 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- |||||||||| Trial primary completion date: Proton or Photon RT for Retroperitoneal Sarcomas (clinicaltrials.gov) - Feb 3, 2017
P1/2, N=80, Recruiting, Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- |||||||||| Review, Journal: Surgical Management of Primary Scrotal Cancer. (Pubmed Central) - Feb 1, 2017
Analysis of outcomes suggests that high-risk scrotal cancer may have a worse prognosis compared with penile cancer, and low-risk scrotal cancer may have a comparable prognosis. Understanding techniques for management and survival outcomes can help the urologist determine the appropriate course of treatment and improve patient care.
- |||||||||| mitomycin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: HIPEC/IPHC: Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (clinicaltrials.gov) - Feb 1, 2017 P2, N=200, Recruiting, Understanding techniques for management and survival outcomes can help the urologist determine the appropriate course of treatment and improve patient care. Trial primary completion date: Sep 2016 --> Jan 2018
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab Beyond Progression (BBP) (clinicaltrials.gov) - Jan 30, 2017 P2, N=68, Active, not recruiting, Trial primary completion date: Oct 2016 --> Oct 2020 Trial primary completion date: Dec 2016 --> Dec 2019
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial suspension, Combination therapy, PD(L)-1 Biomarker, Metastases: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - Jan 30, 2017 P2, N=12, Suspended, Trial primary completion date: Feb 2017 --> Dec 2017 N=37 --> 12 | Active, not recruiting --> Suspended
- |||||||||| Bavencio (avelumab) / EMD Serono
Enrollment open, Trial initiation date, PD(L)-1 Biomarker: OSTPDL1: A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma (clinicaltrials.gov) - Jan 28, 2017 P2, N=40, Recruiting, The results of this study suggest mitochondrial dysfunction is associated with dynamic change that is involved in the apoptosis and anti-angiogenesis elicited by P. urinaria. Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Jan 2017
- |||||||||| Review, Journal: Dermatofibrosarcoma Protuberans. (Pubmed Central) - Jan 27, 2017
Understanding the molecular pathogenesis has resulted in use of tyrosine kinase inhibitor therapy for patients with locally advanced disease or in metastatic disease. DFSP patients require long-term follow-up.
- |||||||||| Review, Journal: Management of Gastrointestinal Stromal Tumors. (Pubmed Central) - Jan 27, 2017
This article reviews how surgery and systemic therapy are being used, incorporating definitions of risk. Decisions on how to treat a patient is based on the risk of progression, pathologic characteristics, and tumor location.
- |||||||||| Review, Journal: The Role for Radiation Therapy in the Management of Sarcoma. (Pubmed Central) - Jan 27, 2017
Best practices require ample communication between the radiation and surgical teams to ensure appropriate tissues are targeted, unnecessary radiation is avoided, and patients are afforded the best opportunity for cure while maintaining function. Modern experiences with intensity-modulated radiotherapy/image-guided radiation therapy suggest toxicity is reduced through field size reduction and precise targeting, improving the therapeutic ratio.
- |||||||||| Review, Journal: Systemic Therapy for Advanced Soft Tissue Sarcoma. (Pubmed Central) - Jan 27, 2017
Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.
- |||||||||| Votrient (pazopanib) / Novartis
Trial primary completion date, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma (clinicaltrials.gov) - Jan 26, 2017 P2, N=30, Recruiting, It also emphasizes the importance of histopathologic findings as the established diagnostic gold standard and the need to interpret molecular results within the clinical context. Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Review, Journal: Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. (Pubmed Central) - Jan 24, 2017
Considering its association with poor treatment response and prognosis of lung cancer, developing an effective inhibitory approach is urgently needed. Here, we review different strategies currently being explored to target KRAS-mutant NSCLC, discuss opportunities and challenges, and also propose some novel methods and concepts with the promise of clinical application.
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Jan 24, 2017 P1, N=18, Active, not recruiting, Here, we review different strategies currently being explored to target KRAS-mutant NSCLC, discuss opportunities and challenges, and also propose some novel methods and concepts with the promise of clinical application. Trial primary completion date: Jun 2017 --> Jan 2017
- |||||||||| lorvotuzumab mertansine (IMGN901) / AbbVie
Enrollment closed, Enrollment change: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (clinicaltrials.gov) - Jan 24, 2017 P2, N=62, Active, not recruiting, Trial primary completion date: Jun 2017 --> Jan 2017 Recruiting --> Active, not recruiting | N=150 --> 62
|